论文部分内容阅读
INTRODUCTION Hypertension,a presently rapidly expanding disease, has been becoming a major risk factor for cardiocerebrovascular events and was called “silent killer” by American Associated Press. It is estimated that nearly one billion people are affected by hypertension worldwide, and this figure is predicted to increase to 1.5 billion by 2025. At present, there are over a hundred and sixty million hypertension patients in China, and the prevalence of hypertension is increasing progressively. Despite the fact that many effective drugs, including calcium-channel blocker (CCB), diuretics, angiotensin-converting enzyme inhibitor (ACEI), angiotensin-receptor blocker (ARB),β blocker and so on, are available for patients and clinicians, only about one third of patients have their blood pressure successfully controlled.
INTRODUCTION Hypertension, a presently rapidly expanding disease, has been a major risk factor for cardiocerebrovascular events and was called “silent killer ” by American Associated Press. It is estimated that nearly one billion people are affected by hypertension worldwide, and this figure is the predicted to increase to 1.5 billion by 2025. At present, there are over a hundred and sixty million hypertension patients in China, and the prevalence of hypertension is increasing progressively. Despite the fact that many effective drugs, including calcium-channel blocker (CCB ), diuretics, angiotensin-converting enzyme inhibitor (ACEI), angiotensin-receptor blocker (ARB), beta blocker and so on, are available for patients and clinicians, only about one third of patients have their blood pressure successfully controlled.